Navigation Links
Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
Date:11/11/2008

CAMBRIDGE, England, November 11 /PRNewswire-FirstCall/ --

- ("Stem Cell Sciences", "SCS", "the Company")

Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, announces that it has licensed IRES technology to a leading provider of genetically modified rat and mouse models for medical and pharmaceutical research. Under the terms of the multi-year agreement, which is non-exclusive and retroactive, the undisclosed partner will gain access to the IRES technology for use in its own research and development activities. Under the terms of the licence, SCS will receive US$750,000 over six years plus royalties.

SCS' IRES (Internal Ribosome Entry Site) technology enables researchers to monitor the activity of a particular gene of interest in living cells or tissues without blocking the normal function of the gene. In particular, IRES is important for evaluating the success of gene knock-outs or knock-ins in stem cells, which is crucial for the successful creation of transgenic mouse and rat disease models.

Dr Alastair Riddell, CEO of SCS, said "A key element of our commercial strategy is to realise both immediate and longer-term value from our extensive IP portfolio in the stem cell field through licence agreements such as this. We are therefore very pleased to have signed this agreement with one of the leading providers of transgenic animal models to the pharmaceutical research industry. We are continuing discussions with other companies, which may benefit from the use of SCS technology in conjunction with their own, and are optimistic of signing further agreements in the coming months."

About Stem Cell Sciences plc

Stem Cell Sciences (SCS) is an international research and development company focusing on the commercial application of stem cell biology technologies for drug discovery and regenerative medicine research. Stem Cell Sciences is now focussing on building revenues through the sale of products, collaborative research and licensing deals with international biotechnology and pharmaceutical companies.

Stem Cell Sciences has a substantial portfolio of patents and patent applications in both adult and embryonic stem cell fields. The Company has been active in the stem cell research field since 1994, principally focused on technologies to grow, differentiate, and purify adult and embryonic stem cells. These include technologies to permit the generation of highly purified stem cells and their differentiated progeny (specialised tissue cell types) for use in genetic, pharmacological and toxicological screens. Moreover, these technologies may be able to provide pure populations of appropriate cell types for transplantation therapies in the future.

The Company has its main research base and headquarters in Cambridge, UK with a second research base in Monash near Melbourne, Australia and a business development office in San Francisco, USA.

For further information on the company please visit: http://www.stemcellsciences.com.

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)

Alastair Riddell, CEO

Tim Allsopp, Chief Scientific Officer

+44(0)1223-499160

Stem Cell Sciences pty ltd (Australia)

Paul Bello, Operations Manager

+61(0)400-500-495

Citigate Dewe Rogerson (UK)

Mark Swallow / Emma Palmer Foster / Amber Bielecka

+44(0)20-7638-9571

Talk Biotech (Australia)

Fay Weston, Director

+61(0)422-206-036

Daniel Stewart & Company (NOMAD to SCS, UK)

Simon Leathers / Simon Starr

+44(0)207-776-6566


'/>"/>
SOURCE Stem Cell Sciences plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/23/2017)... -- Hunova, the first robotic gym for the rehabilitation and functional motor sense ... Genoa, Italy . The first 30 robots will be available ... USA . The technology was developed and patented at the IIT ... Movendo Technology thanks to a 10 million euro investment from entrepreneur Sergio ... ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
Breaking Biology News(10 mins):